Effective interventions in overweight or obese young children: systematic review and meta-analysis

Esther van Hoek1, Edith J M Feskens, Laura I Bouwman

  • 11 Department of Pediatrics, Gelderse Vallei Hospital , Ede, The Netherlands .

Childhood Obesity (Print)
|October 22, 2014
PubMed

Insights

Multicomponent treatment programs combining diet, physical activity, and behavioral therapy are most effective for treating overweight young children. Moderate to high intensity programs showed the largest improvements in BMI z-score.

Area of Science:

  • Pediatric Obesity Research
  • Public Health Interventions
  • Evidence-Based Medicine

Background:

  • Effectiveness of childhood obesity treatment programs varies.
  • Key characteristics of successful interventions remain unclear.
  • Systematic review and meta-analysis to evaluate treatment effectiveness.

Purpose of the Study:

  • To systematically review and meta-analyze the effectiveness of treatment programs for overweight and obese young children.
  • To identify characteristics of effective interventions for pediatric obesity.

Main Methods:

  • Comprehensive literature search of PubMed, Embase, Web of Science, and PsycINFO databases up to April 2012.
  • Inclusion criteria: studies on overweight/obese children (mean age 3-8 years) reporting BMI z-score change.
  • Random-effects model meta-analysis used to pool data from eligible studies.

Main Results:

  • 27 articles were included, with 11 studies (1015 participants) eligible for meta-analysis.
  • High heterogeneity observed in pooled intervention effects.
  • Subgroup analysis revealed multicomponent programs (diet, physical activity, behavioral therapy) of moderate/high intensity showed the largest BMI z-score reduction (-0.46).

Conclusions:

  • Multicomponent treatment programs, particularly those of moderate to high intensity, show promise for effectively treating overweight young children.
  • Further research with larger sample sizes is warranted to confirm these findings.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
353
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
972
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
391
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
317
Binge Eating Disorders01:23

Binge Eating Disorders

Binge eating disorder is a significant mental health condition characterized by recurrent episodes of excessive food consumption within a short period, accompanied by a perceived loss of control over eating behavior. Unlike occasional overeating, binge eating disorder is marked by distressing emotions such as guilt, shame, and anxiety following binge episodes. The disorder affects individuals across different ages and backgrounds, with profound implications for physical and psychological...
798